Bull case
CTVA would need investors to value it at roughly 41x earnings — about 20x more generous than today's 21x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Three scenarios for where CTVA stock could go
CTVA would need investors to value it at roughly 41x earnings — about 20x more generous than today's 21x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
At 31x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
If investor confidence fades or macro conditions deteriorate, a 2x multiple contraction could push CTVA down roughly 7% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.

Corteva is a global agricultural science company that develops seeds and crop protection products for farmers worldwide. It generates revenue primarily through its Seed segment (~60% of sales) and Crop Protection segment (~40%), selling proprietary seed genetics, traits, and chemical solutions. The company's competitive advantage lies in its extensive R&D pipeline—one of the largest in agriculture—and its portfolio of patented seed traits and crop protection technologies.
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $2.20/$1.89 | +16.4% | $6.5B/$6.3B | +3.0% |
| Q4 2025 | $-0.23/$-0.51 | +54.6% | $2.6B/$2.5B | +6.0% |
| Q1 2026 | $0.22/$0.22 | -1.3% | $3.9B/$4.2B | -7.8% |
| Q2 2026 | $1.50/$1.17 | +28.2% | $4.9B/$4.6B | +5.7% |
CTVA beat EPS estimates in 3 of 4 tracked quarters. A strong delivery record supports forward estimate credibility.
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest annual revenue by segment or product family
Tap, hover, or focus a slice to inspect segment detail.
Latest annual revenue by reported region
Tap, hover, or focus a slice to inspect segment detail.
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Fair value est. $42 — implies -46.7% from today's price.
| Metric | CTVA | S&P 500 | Basic Materials | 5Y Avg CTVA |
|---|---|---|---|---|
| Forward PE | 21.0x | 18.8x+12% | 14.9x+41% | — |
| Trailing PE | 49.1x | 24.4x+101% | 23.6x+108% | 37.9x+30% |
| PEG Ratio | 4.11x | 1.66x+148% | 1.23x+234% | — |
| EV/EBITDA | 13.3x | 15.2x-13% | 11.0x+21% | 11.7x+13% |
| Price/FCF | 18.7x | 20.7x | 29.0x-35% | 49.3x-62% |
| Price/Sales | 3.0x | 3.1x | 1.9x+61% | 2.3x+31% |
| Dividend Yield | 0.90% | 1.91% | 1.41% | 1.12% |
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolCTVA generates $2.1B in free cash flow at a 11.5% margin — returns 2.9% of market cap to shareholders annually.
Revenue, margins, and cash generation
ROIC, leverage, and debt serviceability
How capital is returned to owners
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageKey factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 17, 2026
A 10% decline in farmer net income could reduce Corteva's revenue growth by 150-200 bps, potentially leading to flat revenue growth.
A global recession could result in flat revenue and only +5% EPS growth, significantly below historical averages.
CTVA trades 10.2% below its 52-week high, indicating potential valuation concerns or market skepticism.
Corteva's narrow moat may limit pricing power and competitive advantages in challenging market conditions.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 17, 2026
Corteva Inc. has a narrow moat, providing competitive advantages in its industry.
Vanguard Group is the top holder with 12% ownership, indicating strong institutional confidence.
Full equity research reports include investment thesis, valuation methods, and buy/sell recommendations.
A bullish thesis on Corteva highlights positive outlooks from Business Model Mastery.
Corteva maintains a dedicated Investor Relations website, providing transparency and business updates.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
CTV CTVA Corteva, Inc. | $52.7B | 21.0x | +2.3% | 6.5% | Buy | +13.5% |
FMC FMC FMC Corporation | $1.4B | 6.8x | +2.7% | -72.9% | Hold | +39.4% |
CF CF CF Industries Holdings, Inc. | $15.8B | 6.0x | +9.8% | 23.7% | Buy | +8.7% |
MOS MOS The Mosaic Company | $7.3B | 27.8x | +3.6% | 6.0% | Hold | +22.3% |
NTR NTR Nutrien Ltd. | $30.2B | 11.0x | +3.6% | 8.6% | Buy | +30.4% |
AMG AMGN Amgen Inc. | $182.2B | 15.1x | +6.2% | 20.9% | Buy | +3.5% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
CTVA returns capital mainly through $1.1B/year in buybacks (2.0% buyback yield), with a modest 0.90% dividend — combining for 2.9% total shareholder yield. The dividend has grown for 7 consecutive years.
Yield, cadence, and growth quality
How much per-share support comes from repurchases
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.36 | — | — | — |
| 2025 | $0.70 | +6.1% | 2.4% | 3.4% |
| 2024 | $0.66 | +6.5% | 2.5% | 3.7% |
| 2023 | $0.62 | +6.9% | 2.2% | 3.5% |
| 2022 | $0.58 | +7.4% | 2.3% | 3.3% |
Common questions answered from live analyst data and company financials.
Corteva, Inc. (CTVA) is rated Buy by Wall Street analysts as of 2026. Of 37 analysts covering the stock, 23 rate it Buy or Strong Buy, 12 rate it Hold, and 2 rate it Sell or Strong Sell. The consensus 12-month price target is $89, implying +13.5% from the current price of $79. The bear case scenario is $73 and the bull case is $152.
The Wall Street consensus price target for CTVA is $89 based on 37 analyst estimates. The high-end target is $95 (+20.9% from today), and the low-end target is $82 (+4.4%). The base case model target is $115.
CTVA trades at 21.0x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals expensive versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
The primary risks for CTVA in 2026 are: (1) Global recession risk — A global recession could result in flat revenue and only +5% EPS growth, significantly below historical averages. (2) Farmer income sensitivity — A 10% decline in farmer net income could reduce Corteva's revenue growth by 150-200 bps, potentially leading to flat revenue growth. (3) Valuation pressure — CTVA trades 10. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
Analyst consensus estimates CTVA will report consensus revenue of $18.3B (+2.3% year-over-year) and EPS of $2.39 (+38.7% year-over-year) for the upcoming fiscal year. The following year, analysts project $18.8B in revenue.
Corteva, Inc. is expected to report its next earnings on approximately 2026-07-30. Consensus expects EPS of $2.22 and revenue of $6.6B. Over recent quarters, CTVA has beaten EPS estimates 83% of the time.
Corteva, Inc. (CTVA) generated $2.1B in free cash flow over the trailing twelve months — a free cash flow margin of 11.5%. CTVA returns capital to shareholders through dividends (0.9% yield) and share repurchases ($1.1B TTM).